Randomized controlled trial: Lisinopril reduces proteinuria, ammonia, and renal polypeptide tubular catabolism in patients with chronic allograft nephropathy

Transplantation

Volumn 89, Issue 1, 2010, Pages 104-114

  Amara, Alieu B ^a   Sharma, Asheesh ^a   Alexander, John L ^b   Alfirevic, Ana ^a   Mohiuddin, Atif ^b   Pirmohamed, Munir ^a   Close, Graeme L ^a   Grime, Steve ^b   Maltby, Paul ^b   Shawki, Howida ^b   Heyworth, Sally ^b   Shenkin, Alan ^a   Smith, Linda ^b   Sharma, Ajay K ^b   Hammad, Abdel ^b   Rustom, Rana ^a,b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Angiotensinconverting enzyme inhibitors.; Chronic allograft nephropathy; Proteinuria; Renal proximal tubule peptide catabolism

Indexed keywords

ALDOSTERONE; AMMONIA; ANGIOTENSINOGEN; APROTININ; BICARBONATE; LISINOPRIL; POLYPEPTIDE; POTASSIUM;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; AMMONIA BLOOD LEVEL; ARTICLE; BICARBONATE BLOOD LEVEL; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; FEMALE; GENOTYPE; GRAFT SURVIVAL; HISTOPATHOLOGY; HUMAN; MALE; MEAN ARTERIAL PRESSURE; METABOLIC ACIDOSIS; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM;

AMMONIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; CADAVER; CREATININE; GENOTYPE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY TRANSPLANTATION; KIDNEY TUBULES; LISINOPRIL; LIVING DONORS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEINURIA; SURVIVAL ANALYSIS; SURVIVORS; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 74549156314     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181bf13d9     Document Type: Article

References (68)

1. Briganti EM, Russ GR, McNeil JJ, et al. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 2002; 347: 103.
2. Chapman JR, O'Connell PJ, Nankivell BJ. Chronic renal allograft dysfunction. J Am Soc Nephrol 2005; 16: 3015.
3. Hariharan S, McBride MA, Cherikh WS, et al. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62: 311.
4. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: Have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004; 4: 1289.
5. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326.
6. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in protein-uric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997; 349: 1857.
7. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropa-thy due to type 2 diabetes. N Engl J Med 2001; 345: 851.
8. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regressionofrenal lesions ofchronic nephropathies and diabetes. J Clin Invest 2006; 116: 288.
9. Zhang Z, Shahinfar S, Keane WF, et al. Importance of baseline distribution of proteinuria in renal outcomes trials: Lessons from the reduction of end-points in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. J Am Soc Nephrol 2005; 16: 1775.
10. Hiremath S, Fergusson D, Doucette S, et al. Renin angiotensin system blockade in kidney transplantation: A systematic review of the evidence. Am J Transplant 2007; 7: 2350.
11. Rustom R, Paraoan MT, Sells RA, et al. Effects of angiotensin-converting- enzyme inhibitors on progression to end-stage renal failure in chronic vascular rejection. Transplant Proc 2001; 33: 1175.
12. Fernandez-Fresnedo G, Plaza JJ, Sanchez-Plumed J, et al. Proteinuria: A new marker of long-term graft and patient survival in kidney transplantation. Nephrol Dial Transplant 2004; 19(suppl 3): iii47.
13. Rustom R, Grime JS, Sells RA, et al. Renal tubular peptide catabolism in chronic vascular rejection. Ren Fail 2001; 23: 517.
14. Barnas U, Schmidt A, Haas M, et al. The effects of prolonged angiotensin-converting enzyme inhibition on excretory kidney function and pro-teinuria in renal allograft recipients with chronic progressive transplant failure. Nephrol Dial Transplant 1996; 11: 1822.
15. Artz MA, Hilbrands LB, Borm G, et al. Blockade of the renin-angiotensin system increases graft survival in patients with chronic allograft ne-phropathy. Nephrol Dial Transplant 2004; 19: 2852.
16. Bone JM, Amara AB, ShenkinA, et al. Calcineurin inhibitors and proximal renal tubular injury in renal transplant patients with proteinuria and chronic allograft nephropathy. Transplantation 2005; 79: 119.
17. Rustom R, Grime JS, Costigan M, et al. Proximal renal tubular peptide catabolism, ammonia excretion and tubular injury in patients with proteinuria: Before and after lisinopril. Clin Sci (Lond) 1998; 94: 425.
18. Rustom R, Grime JS, Costigan M, et al. Oral sodium bicarbonate reduces proximal renal tubular peptide catabolism, ammoniogenesis, and tubular damage in renal patients. Ren Fail 1998; 20: 371.
19. Rustom R, Jackson MJ, CritchleyM, et al. Tubular metabolism ofapro-tinin 99mTc and urinary ammonia: Effects of proteinuria. Miner Electrolyte Metab 1992; 18: 108.
20. Hingorani AD, Jia H, Stevens PA, et al. Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. J Hypertens 1995; 13(12 pt 2): 1602.
21. Scharplatz M, Puhan MA, Steurer J, et al. Does the Angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism modify the response to ACE inhibitor therapy?-A systematic review. Curr Control Trials Cardiovasc Med 2005; 6: 16.
22. Yoshida H, Mitarai T, Kawamura T, et al. Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. J Clin Invest 1995; 96: 2162.
23. Fan X, Wang Y, Sun K, et al. Polymorphisms of ACE2 gene are associated with essential hypertension and antihypertensive effects of Capto-pril in women. Clin Pharmacol Ther 2007; 82: 187.
24. Yakupoglu HY, Corsenca A, Wahl P, et al. Posttransplant acidosis and associated disorders of mineral metabolism in patients with a renal graft. Transplantation 2007; 84: 1151.
25. Moher D, Schulz KF, Altman D. The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001; 285: 1987.
26. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247.
27. Poggio ED, Wang X, Weinstein DM, et al. Assessing glomerular filtration rate by estimation equations in kidney transplant recipients. Am J Transplant 2006; 6: 100.
28. Mayer NJ, Forsyth A, Kantachuvesiri S, et al. Association of the D allele of the angiotensin I converting enzyme polymorphism with malignant vascular injury. Mol Pathol 2002; 55: 29.
29. Anderson ME. Determination of glutathione and glutathione disulfide in biological samples. Methods Enzymol 1985; 113: 548.
30. McArdle A, van der Meulen JH, Catapano M, et al. Free radical activity following contraction-induced injury to the extensor digitorum longus muscles of rats. Free Radic Biol Med 1999; 26: 1085.
31. Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1967; 70: 158.
32. Shenkin A, Baines M, Fell GS, et al. Vitamins and trace elements. In: Burtis CA, Ashwood ER, Bruns DE, eds. Tietz textbook of clinical chemistry and molecular diagnostics. St. Louis, MO: Elsevier Saunders 2006.
33. Thurnham DI, Smith E, Flora PS. Concurrent liquid-chromatographic assay of retinol, alpha-tocopherol, beta-carotene, alpha-carotene, lyco-pene, and beta-cryptoxanthin in plasma, with tocopherol acetate as internal standard. Clin Chem 1988; 34: 377.
34. Elliott P, Hawthorne G. Imputing missing repeated measures data: How should we proceed? Aust N Z J Psychiatry 2005; 39: 575.
35. Unnebrink K, Windeler J. Intention-to-treat: Methods for dealing with missing values in clinical trials of progressively deteriorating diseases. Stat Med 2001; 20: 3931.
36. Altman DG, Bland JM. Missing data. BMJ 2007; 334: 424.
37. Huntington JL, Dueck A. Handling missing data. Curr Probl Cancer 2005; 29: 317.
38. Djamali A, Kendziorski C, Brazy PC, et al. Disease progression and outcomes in chronic kidney disease and renal transplantation. Kidney Int 2003; 64: 1800.
39. Pouteil-Noble C, Maiza H, Remontet L. Post-transplant glomerular filtration rate as a marker for long-term outcome. Ann Transplant 2000; 5: 29.
40. Woo YM, Pereira BJ, Gill JS. Chronic kidney disease progression in native and transplant kidneys. Curr Opin Nephrol Hypertens 2004; 13: 607.
41. Gill JS, Tonelli M, Mix CH, et al. The change in allograft function among long-term kidney transplant recipients. J Am Soc Nephrol 2003; 14: 1636.
42. Mariat C, Alamartine E, Afiani A, et al. Predicting glomerular filtration rate in kidney transplantation: Are the K/DOQI guidelines applicable? Am J Transplant 2005; 5: 2698.
43. White C, Akbari A, Hussain N, et al. Estimating glomerular filtration rate inkidney transplantation:Acomparison between serum creatinine and cystatin C-based methods. J Am Soc Nephrol 2005; 16: 3763.
44. Heinze G, Mitterbauer C, Regele H, et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 2006; 17: 889.
45. Zaltzman JS, Nash M, Chiu R, et al. The benefits of renin-angiotensin blockade in renal transplant recipients with biopsy-proven allograft nephropathy. Nephrol Dial Transplant 2004; 19: 940.
46. Lin J, Valeri AM, Markowitz GS, et al. Angiotensin converting enzyme inhibition in chronic allograft nephropathy. Transplantation 2002; 73: 783.
47. Bohle A, Mackensen-Haen S, von Gise H, et al. The consequences of tubulo-interstitial changes for renal function in glomerulopathies. A morphometric and cytological analysis. Pathol Res Pract 1990; 186: 135.
48. Williams PS, Fass G, Bone JM. Renal pathology and proteinuria determine progression in untreated mild/moderate chronic renal failure. Q J Med 1988; 67: 343.
49. Halimi JM, Laouad I, Buchler M, et al. Early low-grade proteinuria: Causes, short-term evolution and long-term consequences in renal transplantation. Am J Transplant 2005; 5: 2281.
50. Reichel H, Zeier M, Ritz E. Proteinuria after renal transplantation: Pathogenesis and management. Nephrol Dial Transplant 2004; 19: 301.
51. Morigi M, Macconi D, Zoja C, et al. Protein overload-induced NF-kappaB activation inproximal tubular cells requires H(2)O(2) through a PKC-dependent pathway. J Am Soc Nephrol 2002; 13: 1179.
52. Nakajima H, Takenaka M, Kaimori JY, et al. Activation of the signal transducer and activator of transcription signaling pathway in renal proximal tubular cells by albumin. J Am Soc Nephrol 2004; 15: 276.
53. Shalamanova L, McArdle F, Amara AB, et al. Albumin overload induces adaptive responses in human proximal tubular cells through oxidative stress but not via angiotensin II type 1 receptor. Am J Physiol Renal Physiol 2007; 292: F1846.
54. Arias M, Fernandez-Fresnedo G, Rodrigo E, et al. Non-immunologic intervention in chronic allograft nephropathy. Kidney Int Suppl 2005: S118.
55. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 2000; 356: 147.
56. Kasiske BL, Anjum S, Shah R, et al. Hypertension after kidney transplantation. Am J Kidney Dis 2004; 43: 1071.
57. Opelz G, Dohler B. Improved long-term outcomes after renal transplantation associated with blood pressure control. Am J Transplant 2005; 5: 2725.
58. Stigant CE, Cohen J, Vivera M, et al. ACE inhibitors and angiotensin II antagonists in renal transplantation: An analysis of safety and efficacy. Am J Kidney Dis 2000; 35: 58.
59. Tannen RL, Nissim I, Sahi A. Hormonal mediators ofammoniagenesis: Mechanism of action of PGF2 alpha and the implications for other hormones. Kidney Int 1996; 50: 15.
60. Liou HH, Huang TP, Campese VM. Effect of long-term therapy with captopril on proteinuria and renal function in patients with non-insulin-dependent diabetes and with non-diabetic renal diseases. Nephron 1995; 69: 41.
61. Pollock CA, Poronnik P. Albumin transport and processing by the proximal tubule: Physiology and pathophysiology. Curr Opin Nephrol Hypertens 2007; 16: 359.
62. Inigo P, Campistol JM, Lario S, et al. Effects of losartan and amlo-dipine on intrarenal hemodynamics and TGF-beta(1) plasma levels in a crossover trial in renal transplant recipients. J Am Soc Nephrol 2001; 12: 822.
63. Tylicki L, Biedunkiewicz B, Chamienia A, et al. Renal allograft protection with angiotensin II type 1 receptor antagonists. Am J Transplant 2007; 7: 243.
64. Buraczynska M, KsiazekP, Drop A, et al. Genetic polymorphisms ofthe renin-angiotensin system in end-stage renal disease. Nephrol Dial Transplant 2006; 21: 979.
65. Inoue I, Nakajima T, Williams CS, et al. A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J Clin Invest 1997; 99: 1786.
66. Schmidt S, Ritz E. Genetics of the renin-angiotensin system and renal disease: A progress report. Curr Opin Nephrol Hypertens 1997; 6: 146.
67. Tarnow L, Cambien F, Rossing P, et al. Angiotensinogen gene polymorphisms in IDDM patients with diabetic nephropathy. Diabetes 1996; 45: 367.
68. Russ AP, Maerz W, Ruzicka V, Stein U, Gross W. Rapid detection of the hypertension-associated Met2353Thr allele of the human angio-tensinogen gene. Hum Mol Genet 1993; 2: 609.